Updates are available Correction dated 2024-01-23
Click to view Correction: https://doi.org/10.1038/s41467-024-44938-4
-
Authors
Wu, Margaret
Carballo-Jane, Ester
Zhou, Haihong https://orcid.org/0000-0003-3050-3074
Zafian, Peter
Dai, Ge
Liu, Mindy
Lao, Julie
Kelly, Terri
Shao, Dan
Gorski, Judith
Pissarnitski, Dmitri
Kekec, Ahmet
Chen, Ying
Previs, Stephen F.
Scapin, Giovanna
Gomez-Llorente, Yacob
Hollingsworth, Scott A. https://orcid.org/0000-0003-3294-0083
Yan, Lin
Feng, Danqing
Huo, Pei
Walford, Geoffrey
Erion, Mark D.
Kelley, David E.
Lin, Songnian
Mu, James https://orcid.org/0000-0001-8081-2401
- License Information
-
More Information
Article History
Received: 2 September 2021
Accepted: 17 January 2022
First Online: 17 February 2022
Change Date: 23 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-44938-4
Competing interests
: All authors are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. Some IRPA dimers discussed here are covered in patent publication WO 2016/081670, which disclose Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor. Arising from the publication are patents that have granted in Australia, Canada, China, Germany, France, Great Britain, Japan, South Korea, Russia and United States, and patent applications that are pending in BR, IN, and MX as of December 09, 2021. Merck Sharp & Dohme Corp., is the applicant of the patent and the inventors are S.L., L.Y., P.H., D.P., D.F., Y.Z., C.B.-D., Z.-C.S., Z.W. and Y.M.
